Avenge Bio Revenue and Competitors
Estimated Revenue & Valuation
- Avenge Bio's estimated annual revenue is currently $2.6M per year.
- Avenge Bio's estimated revenue per employee is $77,500
- Avenge Bio's total funding is $45M.
Employee Data
- Avenge Bio has 33 Employees.
- Avenge Bio grew their employee count by 6% last year.
Avenge Bio's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Senior Director Product Development | Reveal Email/Phone |
2 | Executive Assistant & Office Manager | Reveal Email/Phone |
3 | Quality Assurance Manager | Reveal Email/Phone |
Avenge Bio Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is Avenge Bio?
Avenge Bio was founded by an experienced team of proven biotech executives to develop transformative therapeutics which can potentially eradicate intractable solid tumors. Avenge Bio is developing our proprietary, allogeneic LOCOcyteTM platform for precision delivery of cytokines and other highly potent immunomodulatory molecules for a controlled period of time. Through this approach we are able to generate robust, local and systemic anti-tumor immune responses, without the toxicities associated with traditional immunotherapies. The LOCOcyteTM platform was developed from extensive research and experience of Dr. Omid Veiseh at Rice University and supported by Longitude Capital, CAM Capital, Perceptive Xontogeny, Rock Springs, Pappas Capital, and other leading healthcare investors. Together we are using the strength and efficiency of our platform to create a broad pipeline of therapeutics that target a wide range of difficult to treat solid tumors.
keywords:N/A
$45M
Total Funding
33
Number of Employees
$2.6M
Revenue (est)
6%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in Natick
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $2.6M | 33 | 38% | $28.9M |
#2 | $6.2M | 34 | 3% | N/A |
#3 | $3.9M | 34 | N/A | N/A |
#4 | $7M | 35 | -3% | N/A |
#5 | $2.8M | 35 | 6% | N/A |